Clinical response to ustekinumab in CARD14-associated papulosquamous eruption (CAPE) with a new missense mutation in CARD14: a case report and systematic review

Nieto-Benito, L.M. (Lula M.); Baniandrés-Rodríguez, O. (O.); Moreno, A. (A.); Hernandez, A. (A.); Torrelo, A. (Antonio); Campos-Domínguez, M. (M.)

Autor(es):

Nieto-Benito, L.M. (Lula M.)

Baniandrés-Rodríguez, O. (O.)

Moreno, A. (A.)

Hernandez, A. (A.)

Torrelo, A. (Antonio)

Campos-Domínguez, M. (M.)

Palabras clave :

Materias Investigacion::Ciencias de la Salud
Materias Investigacion::Ciencias de la Salud::Dermatología
CARD14-associated papulosquamous eruption (CAPE)
CARD14

Fecha de publicación :

2020

Editorial :

Wiley

ISSN :

1468-3083

Cita:

Nieto-Benito, L.M. (Lula M.); Baniandrés-Rodríguez, O. (O.); Moreno, A. (A.); et al. "Clinical response to ustekinumab in CARD14-associated papulosquamous eruption (CAPE) with a new missense mutation in CARD14: a case report and systematic review". Journal of the European Academy of Dermatology and Venereology. 34 (11), 2020, e728 - e730

Resumen

The term CAPE was first introduced by Craiglow et al.1 to define a papulosquamous eruption due to mutations in CARD14 in patients who display characteristics of both psoriasis and pityriasis rubra pilaris (PRP). Heterozygous mutations in CARD14 have been described in psoriasis2 and PRP3, 4 patients, indicating that these disorders share a common underlying pathophysiology.

URI :

https://hdl.handle.net/10171/68853

DOI:

10.1111/jdv.16548

Aparece en las colecciones:

DA - CUN - Dermatología médico-quirúrgica y venereológica - Artículos de revista

Ficheros en este ítem: